View Item 

Show simple item record

Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized Studies
dc.contributor.authorVitko, Stefanen_US
dc.contributor.authorTedesco, Helioen_US
dc.contributor.authorEris, Josetteen_US
dc.contributor.authorPascual, Julioen_US
dc.contributor.authorWhelchel, Johnen_US
dc.contributor.authorMagee, John C.en_US
dc.contributor.authorCampbell, Scotten_US
dc.contributor.authorCivati, Giovannien_US
dc.contributor.authorBourbigot, Bernarden_US
dc.contributor.authorFilho, Gentil Alvesen_US
dc.contributor.authorLeone, Johnen_US
dc.contributor.authorGarcia, Valter Duroen_US
dc.contributor.authorRigotti, Paoloen_US
dc.contributor.authorEsmeraldo, Ronaldoen_US
dc.contributor.authorCambi, Vincenzoen_US
dc.contributor.authorHaas, Tomasen_US
dc.contributor.authorJappe, Annetteen_US
dc.contributor.authorBernhardt, Peteren_US
dc.contributor.authorGeissler, Johannaen_US
dc.contributor.authorCretin, Nathalieen_US
dc.date.accessioned2010-06-01T21:37:07Z
dc.date.available2010-06-01T21:37:07Z
dc.date.issued2004-04en_US
dc.identifier.citationVitko, Stefan; Tedesco, Helio; Eris, Josette; Pascual, Julio; Whelchel, John; Magee, John C.; Campbell, Scott; Civati, Giovanni; Bourbigot, Bernard; Filho, Gentil Alves; Leone, John; Garcia, Valter Duro; Rigotti, Paolo; Esmeraldo, Ronaldo; Cambi, Vincenzo; Haas, Tomas; Jappe, Annette; Bernhardt, Peter; Geissler, Johanna; Cretin, Nathalie (2004). "Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized Studies." American Journal of Transplantation 4(4): 626-635. <http://hdl.handle.net/2027.42/74668>en_US
dc.identifier.issn1600-6135en_US
dc.identifier.issn1600-6143en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74668
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15023156&dopt=citationen_US
dc.format.extent117700 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherMunksgaard International Publishersen_US
dc.publisherBlackwell Publishing Ltden_US
dc.rightsBlackwell Munksgaard 2004en_US
dc.subject.otherCyclosporineen_US
dc.subject.otherEverolimusen_US
dc.subject.otherImmunosuppressive Regimenen_US
dc.subject.otherRenal Functionen_US
dc.subject.otherTherapeutic Drug Monitoringen_US
dc.subject.otherTransplantationen_US
dc.titleEverolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized Studiesen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Transplant Surgery, University of Michigan Medical Center, Ann Arbor, MI, USA,en_US
dc.contributor.affiliationotherTransplant Centre IKEM, Prague, Czech Republicen_US
dc.contributor.affiliationotherDivision of Nephrology, Hospital do Rim e Hipertensao, Sao Paolo, Brazilen_US
dc.contributor.affiliationotherRoyal Prince Alfred Hospital, Sydney, Australiaen_US
dc.contributor.affiliationotherServicio de Nefrologia, Hospital Ramon y Cajal, Madrid, Spainen_US
dc.contributor.affiliationotherOrgan Transplant Services, Piedmont Hospital, Atlanta, Georgia, USAen_US
dc.contributor.affiliationotherPrincess Alexandra Hospital, Brisbane, Queensland, Australiaen_US
dc.contributor.affiliationotherDivisione Nefrologia e Dialisi, Az. Osp. Niguarda Ca′ Granda, Milano, Italyen_US
dc.contributor.affiliationotherService de Nephrologie, CHU, Cavalla Blanche, Brest, Franceen_US
dc.contributor.affiliationotherHospital das ClÍnicas – UNICAMP, Campinas, Sp, Brazilen_US
dc.contributor.affiliationotherLifelink Transplant Institute, Tampa General Hospital, Tampa, Florida, USAen_US
dc.contributor.affiliationotherSanta Casa de MisericÓridia de Porto Alegre, RS, Brazilen_US
dc.contributor.affiliationotherDepartment of Medical and Surgical Sciences, Policlinico Hospital, Padua, Italyen_US
dc.contributor.affiliationotherHospital Geral de Fortaleza – Setor de Transplante Renal, Fortaleza, CearÁ, Brazilen_US
dc.contributor.affiliationotherDepartment of Medicine and Nephrology, Maggiore Hospital, Parma, Italyen_US
dc.contributor.affiliationotherBusiness Unit Transplantation, Novartis Pharma AG, Basel, Switzerlanden_US
dc.identifier.pmid15023156en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74668/1/j.1600-6143.2004.00389.x.pdf
dc.identifier.doi10.1111/j.1600-6143.2004.00389.xen_US
dc.identifier.sourceAmerican Journal of Transplantationen_US
dc.identifier.citedreferenceHariharan S, Johnson CP, Bresnahan BA, Taranto SE, Mcintosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 96. N Engl J Med 2000; 342: 605 – 612.en_US
dc.identifier.citedreferenceHariharan S, Mcbride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311 – 318.en_US
dc.identifier.citedreferenceKahan BD, Chang JY, Sehgal SN. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 1991; 52: 185 – 191.en_US
dc.identifier.citedreferenceNashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit 2002; 24: 53 – 58.en_US
dc.identifier.citedreferenceSehgal S. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660 – 665.en_US
dc.identifier.citedreferenceSchuler W, Sedrani R, Cottens S et al.. SDZ RAD, a new rapamycin derivative: pharmacologic properties in vitro and in vivo. Transplantation 1997; 64: 36 – 42.en_US
dc.identifier.citedreferenceHausen B, Boeke K, Berry GJ, Segarra IT, Christians U, Morris RE. Suppression of acute rejection in allogenic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant 1999; 18: 150 – 159.en_US
dc.identifier.citedreferenceSchuurman H-J, Cottens S, Fuchs S et al.. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997; 64: 32 – 35.en_US
dc.identifier.citedreferenceSerkova N, Hausen B, Berry GJ et al.. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J Pharmacol Exp Ther 2000; 294: 323 – 332.en_US
dc.identifier.citedreferenceHausen B, Boeke K, Berry GJ et al.. Coadministration of Neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability by staggered simultaneous treatment. Transplantation 1999; 67: 956 – 962.en_US
dc.identifier.citedreferenceVitko S, Margreiter R, Weimar W et al.. and the RAD 201 Study Group. International, double-blind, parallel-group study of the safety and efficacy of Certican™ (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral ® and steroids. Am J Transplant 2001; 1 ( Suppl. 1 ): 474, (Abstract) 1337.en_US
dc.identifier.citedreferenceKaplan B, Tedesco-Silva H, Mendez R et al.. and the RAD 251 Study Group. North/South American, double-blind, parallel group study of the safety and efficacy of Certican™ (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral ® and corticosteroids. Am J Transplant 2001; 1 ( Suppl. 1 ): 475, (Abstract) 1339.en_US
dc.identifier.citedreferenceCurtis J, Nashan B, Ponticelli C et al.. and the RAD 156 Study Group. One year results of a multicenter, open-Iabel trial on safety, efficacy of Certican™ (RAD) used in combination with Simulect ® corticosteroids and full or reduced dose Neoral ® in renal transplantation. Am J Transplant 2001; 1 ( Suppl. 1 ): 474, (Abstract) 1335.en_US
dc.identifier.citedreferenceKovarik JM, Hsu C-H, Mcmahon L, Berthier S, Rordorf C. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001; 70: 247 – 254.en_US
dc.identifier.citedreferenceKovarik JM, Kaplan B, Tedesco-Silva H et al.. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 2002; 73: 920 – 925.en_US
dc.identifier.citedreferenceBarama A, Perner F, Beauregard-Zollinger L, Prestele H. Absorption profiling of cyclosporine therapy for de novo kidney transplantation: a prospective, randomised study comparing sparse sampling to trough monitoring. Transplantation 2000; 69 ( Suppl. 8 ): S162 ( Abstract 19 ).en_US
dc.identifier.citedreferenceHalloran P, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356 – 1361.en_US
dc.identifier.citedreferenceSindhi R, Lavia MF, Paulling E et al.. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine + rapamycin regimen. Transplantation 2000; 69: 432 – 436.en_US
dc.identifier.citedreferenceNankivell BJ, Gruenewald SM, Allen RD, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683 – 1689.en_US
dc.identifier.citedreferenceCockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31 – 41.en_US
dc.identifier.citedreferenceRacusen LC, Solez K, Colvin RB et al.. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713 – 723.en_US
dc.identifier.citedreferenceKahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 1999; 68: 1526 – 1532.en_US
dc.identifier.citedreferenceKahan BD for The Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356: 194 – 202.en_US
dc.identifier.citedreferenceMacdonald AS, Rapamune Global Study Group. A worldwide, phase III, randomized, controlled safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271 – 280.en_US
dc.identifier.citedreferencePodder H, Stepkowski SM, Napoli KL et al.. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059 – 1071.en_US
dc.identifier.citedreferenceJohnson RWG, Kreis H, Oberbauer R, BrattstrÖm C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777 – 786.en_US
dc.identifier.citedreferenceBasadonna GP, Matas AJ, Gillingham KJ et al.. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993 – 995.en_US
dc.identifier.citedreferenceLeggat JE, Ojo AO, Leichtman AB et al.. Long-term renal allograft survival: prognostic implication of the timing of acute rejection episodes. Transplantation 1997; 63: 1268 – 1272.en_US
dc.identifier.citedreferenceOppenheimer F, Oyen O, Viljoen H, Vitko S, Falcone A, Cremer M. 36-month results of an international study with everolimus for the prevention of allograft rejection in de novo kidney transplant recipients. Am J Transplant 2003; 3 ( Suppl. 5 ): 459 ( Abstract ).en_US
dc.identifier.citedreferenceThervet E, Pfeffer P, Scolari MP et al.. Clinical outcomes during the first 3 months post-transplant in renal allograft recipients managed by C 2 monitoring of cyclosporine microemulsion (Neoral ® ). Transplantation 2003.en_US
dc.identifier.citedreferenceLibby P, Pober JS. Chronic rejection. Immunity 2001; 14: 387 – 397.en_US
dc.identifier.citedreferenceJardine A. Assessing cardiovascular risk profile of immunosuppressive agents. Transplantation 2001; 72: S81 – S88.en_US
dc.identifier.citedreference33.  Margreiter R for the European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741 – 746.en_US
dc.identifier.citedreferenceLebranchu Y, Bridoux F, Buchler M et al.. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48 – 56.en_US
dc.identifier.citedreferenceLawen JG, Davies EA, Mourad G et al.. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003; 75: 37 – 43.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1600-6143.2004.00389.x.pdf
Size:
114.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.